Friday, 20 April 2018 - 21:09
  • it
  • de
  • en
  • fr

Praluent

Regeneron and Sanofi win legal battle against Amgen over Praluent

Regeneron and its partner Sanofi have won their legal battle against Amgen: indeed, a US appeals court yesterday reversed the former ruling preventing the two companies from marketing Praluent. Sanofi’s shares soon rose 1.8%, while Regeneron’s were up 1.6%. By…

Sanofi/Regeneron’s Praluent: positive results in diabetes patients

Sanofi and Regeneron Pharmaceuticals announced positive results from two Phase IIIb/IV ODYSSEY-DM clinical trials conducted in patients with diabetes. Praluent (alirocumab), when administered on top of maximally tolerated doses of statins, significantly reduced LDL-C, the primary endpoint of the ODYSSEY…

Sanofi confident about Praluent marketed again in the US

Sanofi’s CEO Olivier Brandicourt stated at the JPMorgan conference in San Francisco that he feels confident Sanofi will be able to overturn the verdict by the US court, according to which Sanofi’s Praluent infringes a patent of Amgen’s for its…

Praluent patent infringement, Sanofi and Regeneron to appeal

Sanofi and Regeneron Pharmaceuticals announced they will appeal the injunction granted today by the District Court for the District of Delaware, US; preventing the commercialization and manufacturing of Praluent in the US for having infringed two Amgen patents. The two…

Amgen wins patent infringement case against Sanofi/Regeneron (Praluent)

A federal judge rejected the motion related to a patent infringement case between Amgen—which obtained a favorable verdict last March—and Sanofi/Regeneron, Reuters reported. Indeed, in October 2014 Amgen sought to stop sales of Praluent, a drug from the class of…